Patents by Inventor Rachel Eclov

Rachel Eclov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITION OF FOXP3
    Publication number: 20260035421
    Abstract: Provided herein are peptide-based therapeutics that target POXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.
    Type: Application
    Filed: June 13, 2025
    Publication date: February 5, 2026
    Inventors: James LaBelle, Rachel Eclov, Gregory Bird, Loren D. Walensky
  • Compositions and methods for inhibition of FOXP3
    Patent number: 12344643
    Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immuno-suppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: July 1, 2025
    Assignees: The University of Chicago, Dana-Farber Cancer Institute, Inc.
    Inventors: James LaBelle, Rachel Eclov, Gregory Bird, Loren D. Walensky
  • GENE THERAPIES FOR 21-HYDROXYLASE DEFICIENCY
    Publication number: 20240191213
    Abstract: Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxy lase (21OH) protein and related uses for treating 21OH deficiency.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 13, 2024
    Inventors: Clayton BEARD, Kamal BHARUCHA, Pierre BOUGNERES, Eric DAVID, Rachel ECLOV, Rafael ESCANDON, Genevieve LAFORET, Adam SHAYWITZ, Sophie LE FUR
  • COMPOSITIONS AND METHODS FOR INHIBITION OF FOXP3
    Publication number: 20210094990
    Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.
    Type: Application
    Filed: December 7, 2017
    Publication date: April 1, 2021
    Inventors: James LaBelle, Rachel Eclov, Gregory Bird, Loren D. Walensky